Scholarlink

<p>Umbilical cord blood (UCB) transplantation offers significant advantages over conventional grafts, including rapid availability, reduced graft-versus-host disease, and tolerance for HLA mismatches. However, its clinical utility remains limited by low hematopoietic stem cells (HSCs) doses per unit, leading to delayed engraftment and higher graft failure rates in adults. This review synthesizes cutting-edge ex vivo expansion strategies that overcome cell dose limitations. We critically evaluate advances in cytokine cocktails (e.g., SCF/TPO/FLT3L), small-molecule modulators (UM171, SR-1, nicotinamide), Notch pathway activation, MSC co-culture systems, and bioreactor technologies. These approaches enhance HSC yields while preserving stemness. Clinical trials show that expanded products such as NiCord<sup>®</sup> and Zemcelpro<sup>®</sup> speed up neutrophil recovery (9–16 days) and raise one-year survival rates by 15–25% compared with unmanipulated units. Despite these successes, challenges persist in scalability, standardization, and long-term functional stability of expanded HSCs. Emerging synergies with gene editing, epigenetic modulators, and CAR-NK cell manufacturing offer promising avenues for next-generation platforms. By integrating biological insights with bioengineering innovations, optimized expansion protocols hold the potential to transform UCB into a universally accessible graft source, extending its therapeutic reach to diverse patient populations and hematologic conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

“Next-Generation Cord Blood Expansion: Bridging the Cell Dose Gap with Bioengineered Niches and Clinical Breakthroughs”

  • 期刊论文

  • 发表日期：

    2026年1月29日

查看全文
  • Ke Pi,
  • Hamed Soleimani Samarkhazan,
  • Farzaneh Tavakoli,
  • Masoumeh Nouri,
  • Nazli Servatian

摘要

Umbilical cord blood (UCB) transplantation offers significant advantages over conventional grafts, including rapid availability, reduced graft-versus-host disease, and tolerance for HLA mismatches. However, its clinical utility remains limited by low hematopoietic stem cells (HSCs) doses per unit, leading to delayed engraftment and higher graft failure rates in adults. This review synthesizes cutting-edge ex vivo expansion strategies that overcome cell dose limitations. We critically evaluate advances in cytokine cocktails (e.g., SCF/TPO/FLT3L), small-molecule modulators (UM171, SR-1, nicotinamide), Notch pathway activation, MSC co-culture systems, and bioreactor technologies. These approaches enhance HSC yields while preserving stemness. Clinical trials show that expanded products such as NiCord® and Zemcelpro® speed up neutrophil recovery (9–16 days) and raise one-year survival rates by 15–25% compared with unmanipulated units. Despite these successes, challenges persist in scalability, standardization, and long-term functional stability of expanded HSCs. Emerging synergies with gene editing, epigenetic modulators, and CAR-NK cell manufacturing offer promising avenues for next-generation platforms. By integrating biological insights with bioengineering innovations, optimized expansion protocols hold the potential to transform UCB into a universally accessible graft source, extending its therapeutic reach to diverse patient populations and hematologic conditions.